JP2015526696A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015526696A5 JP2015526696A5 JP2015513220A JP2015513220A JP2015526696A5 JP 2015526696 A5 JP2015526696 A5 JP 2015526696A5 JP 2015513220 A JP2015513220 A JP 2015513220A JP 2015513220 A JP2015513220 A JP 2015513220A JP 2015526696 A5 JP2015526696 A5 JP 2015526696A5
- Authority
- JP
- Japan
- Prior art keywords
- cer
- galcer
- glc
- sphingosine
- lipid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261651569P | 2012-05-25 | 2012-05-25 | |
| EP12169517.5A EP2667197B1 (en) | 2012-05-25 | 2012-05-25 | Sensitive efficacy and specificity biomarkers for proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition |
| EP12169517.5 | 2012-05-25 | ||
| US61/651,569 | 2012-05-25 | ||
| PCT/EP2013/060816 WO2013175016A1 (en) | 2012-05-25 | 2013-05-24 | Sensitive efficacy and specificity biomarkers for proprotein convertase subtilisin/kexin type 9 (pcsk9) inhibition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015526696A JP2015526696A (ja) | 2015-09-10 |
| JP2015526696A5 true JP2015526696A5 (https=) | 2016-11-10 |
Family
ID=46146755
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015513220A Pending JP2015526696A (ja) | 2012-05-25 | 2013-05-24 | プロタンパク質転換酵素スブチリシン／ケキシン９型（ｐｃｓｋ９）阻害に対する高感度の有効性および特異性バイオマーカー |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20160146842A2 (https=) |
| EP (1) | EP2667197B1 (https=) |
| JP (1) | JP2015526696A (https=) |
| CN (1) | CN104508488A (https=) |
| CA (1) | CA2875419A1 (https=) |
| ES (1) | ES2552371T3 (https=) |
| WO (1) | WO2013175016A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9255154B2 (en) | 2012-05-08 | 2016-02-09 | Alderbio Holdings, Llc | Anti-PCSK9 antibodies and use thereof |
| CA2903946A1 (en) * | 2013-03-08 | 2014-09-12 | Zora Biosciences Oy | Non-high density lipoprotein derived cvd markers |
| US10184932B2 (en) * | 2015-12-07 | 2019-01-22 | Zora Biosciences Oy | Use of ceramides and LPLs in diagnosing CVD |
| EP3515950A4 (en) | 2016-09-20 | 2020-10-28 | Wuxi Biologics Ireland Limited. | NEW ANTI-PCSK9 ANTIBODIES |
| CN108037275A (zh) * | 2017-12-14 | 2018-05-15 | 北京豪思生物科技有限公司 | 一种用于评估冠状动脉疾病的试剂盒 |
| WO2019119049A1 (en) * | 2017-12-20 | 2019-06-27 | Baker Heart and Diabetes Institute | Method of predicting drug therapeutic responder status and methods of treatment |
| CN109504737A (zh) * | 2018-11-23 | 2019-03-22 | 黄河科技学院 | 一种体外筛选pcsk9抑制剂的方法 |
| WO2022089486A1 (zh) * | 2020-10-28 | 2022-05-05 | 江苏柯菲平医药股份有限公司 | 抑制PCSK9基因表达的siRNA及其修饰物与应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007127192A2 (en) * | 2006-04-24 | 2007-11-08 | Duke University | Lipidomic approaches to determining drug response phenotypes in cardiovascular disease |
| AU2007275365A1 (en) * | 2006-07-17 | 2008-01-24 | Sirna Therapeutics Inc. | RNA interference mediated inhibition of Proprotein Convertase Subtilisin Kexin 9 (PCSK9) gene expression using short interfering nucleic acid (siNA) |
| CA2667894A1 (en) | 2006-11-07 | 2008-05-15 | Merck & Co., Inc. | Antagonists of pcsk9 |
| CN101679527A (zh) * | 2007-04-13 | 2010-03-24 | 诺瓦提斯公司 | 用于调节前蛋白转化酶枯草杆菌蛋白酶/kexin9型(pcsk9)的分子和方法 |
| JOP20080381B1 (ar) | 2007-08-23 | 2023-03-28 | Amgen Inc | بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9) |
| EP2205639B1 (en) | 2007-10-26 | 2015-12-23 | Merck Sharp & Dohme Corp. | Anti-pcsk9 and methods for treating lipid and cholesterol disorders |
| AR070316A1 (es) | 2008-02-07 | 2010-03-31 | Merck & Co Inc | Antagonistas de pcsk9 (proproteina subtilisina-kexina tipo 9) |
| BR112012013092A2 (pt) * | 2009-12-01 | 2016-10-25 | Metanomics Health Gmbh | ''métodos de diagnóstico, método para identificar se um indivíduo necessita de uma terapia contra esclerose múltipla, métodos de determinação e previsão relacionados à esclerose múltipla'' |
| US9285378B2 (en) * | 2010-01-29 | 2016-03-15 | Metanomics Gmbh | Means and methods for diagnosing heart failure in a subject |
| NO2385374T3 (https=) * | 2010-05-05 | 2014-06-07 | ||
| CN103154742B (zh) * | 2010-06-20 | 2017-11-21 | 佐拉生物科学公司 | 用于鉴定高风险冠状动脉疾病患者的脂质组学标志 |
| EP2592422A1 (en) * | 2011-11-08 | 2013-05-15 | Zora Biosciences OY | Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients undergoing statin treatment |
| EP2592423A1 (en) * | 2011-11-08 | 2013-05-15 | Zora Biosciences OY | Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients not undergoing statin treatment |
-
2012
- 2012-05-25 ES ES12169517.5T patent/ES2552371T3/es active Active
- 2012-05-25 EP EP12169517.5A patent/EP2667197B1/en not_active Not-in-force
-
2013
- 2013-05-24 CN CN201380027083.7A patent/CN104508488A/zh active Pending
- 2013-05-24 WO PCT/EP2013/060816 patent/WO2013175016A1/en not_active Ceased
- 2013-05-24 JP JP2015513220A patent/JP2015526696A/ja active Pending
- 2013-05-24 CA CA2875419A patent/CA2875419A1/en not_active Abandoned
- 2013-05-24 US US14/403,075 patent/US20160146842A2/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015526696A5 (https=) | ||
| Menghini et al. | MiR-216a: a link between endothelial dysfunction and autophagy | |
| De Miguel et al. | Exercise plasma boosts memory and dampens brain inflammation via clusterin | |
| JP6388284B2 (ja) | スタチン治療を受けている冠動脈疾患患者の心血管転帰を予測するためのリピドミックバイオマーカー | |
| JP6388283B2 (ja) | スタチン治療を受けていない冠動脈疾患患者の心血管転帰を予測するためのリピドミックバイオマーカー | |
| Xuan et al. | Development of a high coverage pseudotargeted lipidomics method based on ultra-high performance liquid chromatography–mass spectrometry | |
| Raitoharju et al. | Blood hsa-miR-122-5p and hsa-miR-885-5p levels associate with fatty liver and related lipoprotein metabolism—The Young Finns Study | |
| Lee et al. | Reprogrammed lipid metabolism in bladder cancer with cisplatin resistance | |
| CN103154742B (zh) | 用于鉴定高风险冠状动脉疾病患者的脂质组学标志 | |
| CN104769434B (zh) | 用于2型糖尿病的生物标志物 | |
| Itokazu et al. | Reduced GM1 ganglioside in CFTR-deficient human airway cells results in decreased β1-integrin signaling and delayed wound repair | |
| Zhang et al. | KLF4-PFKFB3-driven glycolysis is essential for phenotypic switching of vascular smooth muscle cells | |
| Marshall et al. | Proteomic mapping of proteins released during necrosis and apoptosis from cultured neonatal cardiac myocytes | |
| JP2014532886A5 (https=) | ||
| CN103502820B (zh) | 用于他汀引发的肌肉毒性的灵敏检测的生物标志物 | |
| Abu-Farha et al. | Reduced miR-181d level in obesity and its role in lipid metabolism via regulation of ANGPTL3 | |
| Walss-Bass et al. | X-aptamer technology identifies C4A and ApoB in blood as potential markers for schizophrenia | |
| Yang et al. | Metabolomic profile reveals that ceramide metabolic disturbance plays an important role in thoracic aortic dissection | |
| Anzalone et al. | IL-17A-associated IKK-α signaling induced TSLP production in epithelial cells of COPD patients | |
| Takahashi et al. | Differential proteome analysis of serum proteins associated with the development of type 2 diabetes mellitus in the KK-Ay mouse model using the iTRAQ technique | |
| JP2017535756A5 (https=) | ||
| EP2667197B1 (en) | Sensitive efficacy and specificity biomarkers for proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition | |
| Doppler et al. | Noncanonical atherosclerosis as the driving force in tricuspid aortic valve associated aneurysms-A trace collection | |
| Kawasaki et al. | Next-generation proteomics of serum extracellular vesicles combined with single-cell RNA sequencing identifies MACROH2A1 associated with refractory COVID-19 | |
| Sumi et al. | Hemoglobin resident in the lung epithelium is protective for smooth muscle soluble guanylate cyclase function |